Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 14, 2014, to report on preliminary U.S. net sales for EYLEA® (aflibercept) Injection for the fourth quarter and full year 2013. This information was presented by CEO Dr. Leonard S. Schleifer at the 32nd Annual J.P. Morgan Healthcare Conference. The filing serves to disclose these key sales figures, which are crucial for investors to assess the commercial performance and growth trajectory of a core product. While the 8-K itself does not contain the specific sales numbers, it indicates that the detailed presentation, including these preliminary sales results, is furnished as an exhibit. Investors would need to review Exhibit 99.1 to obtain the actual sales data for EYLEA®. This disclosure is important for understanding Regeneron's revenue generation and market penetration, particularly for a significant drug like EYLEA®.
Key Highlights
- 1Regeneron Pharmaceuticals filed an 8-K on January 14, 2014.
- 2The filing announces a corporate update from CEO Dr. Leonard S. Schleifer at the J.P. Morgan Healthcare Conference.
- 3Key information disclosed relates to preliminary U.S. net sales of EYLEA® for Q4 and full year 2013.
- 4The presentation containing these sales figures is furnished as Exhibit 99.1 to the 8-K.
- 5This report provides investors with insight into the commercial performance of EYLEA®.